Updated Results on Quad: 96-Week Data From Phase 3 Studies

November/December 2012

Two oral presentations presented 96 week data from the two phase 3 treatment studies for the recent approval of the single-tablet, four-drug combination of elvitegravir/cobicistat/tenofovir/FTC, developed as Quad, and now approved as Stribild in the U.S.

Entry criteria for both studies included being treatment-naive and having an eGRF >70 mL/min/1.73m2.

The first study comparing Quad to Atripla, reported similar rates of virologic suppression to <50 copies/mL of 84% vs 82% (difference 2.7%, 95% CI -- 2.9% to 8.3%). This compared to 48-week results of 88% vs 84%, difference (3.6%, 95% CI -1.6% to 8.8%). A sub-group analysis, by baseline viral load below and above 100,000 copies/mL report rates of81% vs 83%. Mean CD4 cell increases were 295 vs 273 cells/mm3.1

Discontinuation rates due to side effect were similar in each arm (5% vs 7%) with greater reporting of CNS side effects (47% vs 66%) and rash (21% vs 31%) with Atripla but higher rates of renal discontinuations with Quad (2%; n=7 vs 0).

Two patients discontinued Quad after week 48 due to serum creatinine increases but without features of proximal renal tubulopathy. Median changes in serum creatinine (mmol/L [mg/dL]) at week 96 in the Quad vs Atripla arms (11.5 vs 0.9 [0.13 vs 0.01]) were similar to those at week 48 (12.4 vs 0.9 [0.14 vs 0.01]).

Quad had smaller median increases (mmol/L [mg/dL]) in total (0.23 vs 0.47 [9 vs 18], p<0.001) and LDL cholesterol (0.23 vs 0.41 [9 vs16], p=0.011), and similar increase in triglycerides (0.05 vs 0.09 [4 vs 8], p=0.41).

In the second study, 96-week results were reported comparing Quad to the boosted PI combination of atazanavir/ritonavir plus tenofovir/FTC, in just over 700 treatment-naive patients.

The proportion of patients with viral load <50 copies/mL at week 96 was 83% vs 82% (difference 1.1%; 95% CI: 4.5%, 6.7%). This compared to 90% vs 87% (difference 3.0%; 95% CI: 1.9% to 7.8%) at week 48, finding Quad to be non-inferior at both timepoints. Results in patients with baseline viral load >100,000 copies/mL were 82% vs 80% (all comparisons, Quad vs ATZ/r respectively).

Mean CD4 cell increases at week 96 were also similar between arms (256 vs 261 cells/mm3).

Discontinuation rates due to side effects were 4% vs 6%, and caused by renal complications in 3 (0.8%) vs 2 (0.6%) of patients. One person in each arm discontinued between week 48 and 96 due to elevated serum creatinine.

Resistance was reported in 2% vs <1% of patients.

Median increases from baseline in serum creatinine (mmol/L [mg/dL]) at week 96 (10.6 vs 7.1 [0.12 vs 0.08]) were similar to those at week 48 (10.6 vs 7.1 [0.12 vs 0.08]).

Quad had smaller increases (mmol/L [mg/dL]) in triglycerides (0.06 vs 0.18 [5 vs 16], p=0.012) but greater increases in total cholesterol (0.36 vs 0.21 [14 vs 8], p=0.046) with similar changes in LDL and HDL cholesterol. Quad had smaller mean decreases (%) in BMD (hip: 3.16 vs -4.19, p=0.069, spine: 1.96 vs 3.54, p=0.049).


  1. Zolopa A et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. Oral abstract O424A.
  2. 2. Fordyce M et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. Oral abstract O424B.

Links to other websites are current at date of posting but not maintained.

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.